

Pavel Barta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/212959/publications.pdf>

Version: 2024-02-01

23
papers

274
citations

1040056
9
h-index

940533
16
g-index

23
all docs

23
docs citations

23
times ranked

456
citing authors

#	ARTICLE	IF	CITATIONS
1	Gefitinib Induces Epidermal Growth Factor Receptor Dimers Which Alters the Interaction Characteristics with 125I-EGF. <i>PLoS ONE</i> , 2011, 6, e24739.	2.5	77
2	Trans-resveratrol, but not other natural stilbenes occurring in food, carries the risk of drug-food interaction via inhibition of cytochrome P450 enzymes or interaction with xenosensor receptors. <i>Toxicology Letters</i> , 2019, 300, 81-91.	0.8	26
3	Impact of assay temperature on antibody binding characteristics in living cells: A case study. <i>Biomedical Reports</i> , 2017, 7, 400-406.	2.0	21
4	Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line. <i>International Journal of Oncology</i> , 2011, 40, 1677-82.	3.3	20
5	Preparation of peptide thioesters using Fmoc strategy through hydroxyl side chain anchoring. <i>Tetrahedron Letters</i> , 2008, 49, 4016-4019.	1.4	15
6	Circumventing the requirement of binding saturation for receptor quantification using interaction kinetic extrapolation. <i>Nuclear Medicine Communications</i> , 2011, 32, 863-867.	1.1	15
7	A comparison of in vitro methods for determining the membrane receptor expression in cell lines. <i>Nuclear Medicine and Biology</i> , 2012, 39, 893-896.	0.6	14
8	Entecavir Interacts with Influx Transporters hOAT1, hCNT2, hCNT3, but Not with hOCT2: The Potential for Renal Transporter-Mediated Cytotoxicity and Drug-Drug Interactions. <i>Frontiers in Pharmacology</i> , 2015, 6, 304.	3.5	12
9	Exploring Time-Resolved Characterization of the Heterogeneity and Dynamics of Ligand-Receptor Interactions on Living Cells. <i>Journal of Analytical Oncology</i> , 2014, 3, .	0.1	9
10	5-Alkylamino-N-phenylpyrazine-2-carboxamides: Design, Preparation, and Antimycobacterial Evaluation. <i>Molecules</i> , 2020, 25, 1561.	3.8	8
11	Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 280-288.	1.0	7
12	The effect of chelator type on <i>in vitro</i> receptor binding and stability in ¹⁷⁷ Lu-labeled cetuximab and panitumumab. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 448-452.	1.0	7
13	Design, synthesis and biological evaluation of substituted 3-amino-N-(thiazol-2-yl)pyrazine-2-carboxamides as inhibitors of mycobacterial methionine aminopeptidase 1. <i>Bioorganic Chemistry</i> , 2022, 118, 105489.	4.1	7
14	The involvement of selected membrane transport mechanisms in the cellular uptake of ¹⁷⁷ Lu-labeled bombesin, somatostatin and gastrin analogues. <i>Nuclear Medicine and Biology</i> , 2015, 42, 1-7.	0.6	6
15	N-Pyrazinoyl Substituted Amino Acids as Potential Antimycobacterial Agents—the Synthesis and Biological Evaluation of Enantiomers. <i>Molecules</i> , 2020, 25, 1518.	3.8	5
16	Improving Antimicrobial Activity and Physico-Chemical Properties by Isosteric Replacement of 2-Aminothiazole with 2-Aminooxazole. <i>Pharmaceuticals</i> , 2022, 15, 580.	3.8	5
17	N-pyridinylbenzamides: an isosteric approach towards new antimycobacterial compounds. <i>Chemical Biology and Drug Design</i> , 2021, 97, 686-700.	3.2	4
18	Preclinical evaluation of anti-VEGFR2 monoclonal antibody ramucirumab labelled with zirconium-89 for tumour imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2021, 64, 262-270.	1.0	4

#	ARTICLE	IF	CITATIONS
19	Synthesis, Biological Evaluation, and In Silico Modeling of N-Substituted Quinoxaline-2-Carboxamides. Pharmaceuticals, 2021, 14, 768.	3.8	4
20	Antiangiogenic Human Monoclonal Antibody Ramucirumab Radiolabelling: In Vitro Evaluation on VEGFR2-positive Cell Lines. Anticancer Research, 2019, 39, 735-744.	1.1	3
21	Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay. Journal of Pharmacological and Toxicological Methods, 2014, 70, 145-151.	0.7	2
22	<i>In vitro</i> evaluation of concentration, labeling effectiveness and stability for ¹³¹ I- ϵ -labeled radioimmunoassay ligand using real-time detection technology. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 80-86.	1.0	2
23	The <i>in vivo</i> disposition and <i>in vitro</i> transmembrane transport of two model radiometabolites of DOTA- ϵ -conjugated receptor-specific peptides labelled with ¹⁷⁷ Lu. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 483-489.	1.0	1